Analysis of effects of MCB3681, the antibacterially active substance of prodrug MCB3837, on human resident microflora as proof of principle

Clinical Microbiology and Infection

Volumn 21, Issue 8, 2015, Pages 767.e1-767.e4

  Dalhoff, A ^a   Rashid, M U ^b   Kapsner, T ^c   Panagiotidis, G ^b   Weintraub, A ^b   Nord, C E ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Morphochem Aktiengesellschaft für kombinatorische Chemie   (Germany)

Author keywords

Antibacterial effects; Clostridium spp.; Enterococcus spp.; MCB3681; Staphylococcus aureus

Indexed keywords

ANTIINFECTIVE AGENT; MCB 3681; MCB 3837; PRODRUG; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL COLONIZATION; BIFIDOBACTERIUM; CLOSTRIDIA; DRUG EFFECT; DRUG EFFICACY; DRUG TRANSFORMATION; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; HUMAN; IN VIVO STUDY; LACTOBACILLUS; MICROFLORA; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; DRUG EFFECTS; INTESTINE; MALE; METABOLISM; MICROBIOLOGY; NORMAL HUMAN; NOSE; OROPHARYNX; SKIN;

BACTERIA (MICROORGANISMS); CLOSTRIDIA; CLOSTRIDIUM; ENTEROCOCCUS; NEGIBACTERIA; POSIBACTERIA; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; GRAM-POSITIVE BACTERIA; HEALTHY VOLUNTEERS; HUMANS; INTESTINES; MALE; MICROBIOTA; NOSE; OROPHARYNX; SKIN;

EID: 84937524312     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2015.05.025     Document Type: Article

References (10)

1. Dalhoff A., Ullmann U. Correlation between pharmacokinetics, pharmacodynamics and efficacy of antibacterial agents in animal models. Eur J Clin Microbiol Infect Dis 1990, 9:479-487.
2. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998, 26:1-12.
3. Andes D., Craig W.A. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Chemother 2002, 19:261-268.
4. MacGowan A., Rogers C., Bowker K. In vitro models, in vivo models, and pharmacokinetics: what can we learn from in vitro models?. Clin Infect Dis 2001, 33(Suppl. 3):214-220.
5. Ambrose P.G., Bhavnani S.M., Rubino C.M., Louie A., Gumbo T., Forrest A., et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007, 44:79-86.
6. Dalhoff A., Weintraub A., Nord C.E. Alternative strategies for proof of principle studies of antibacterial agents. Antimicrob Agents Chemother 2014, 58:4257-4263.
7. Sullivan A., Edlund C., Nord C.E. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 2001, 1:101-114.
8. Rashid M.U., Weintraub A., Nord C.E. Effect of new antimicrobial agents on the ecological balance of human microflora. Anaerobe 2012, 18:249-253.
9. Rashid M.U., Dalhoff A., Bäckström T., Björkhem-Bergman L., Panagiotidis G., Weintraub A., et al. Ecological impact of MCB3837 on the normal human microbiota. Int J Antimicrob Agents Chemother 2014, 44:125-130.
10. Rashid M.U., Dalhoff A., Weintraub A., Nord C.E. In vitro activity of MCB3681 against Clostridium difficile. Anaerobe 2014, 28:216-219.